Navigation Links
Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock
Date:8/6/2013

WASHINGTON, Aug. 6, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Vanda also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. All of the shares in the offering are to be sold by Vanda, with net proceeds to be used for sales and marketing expenditures which may include commercial launch activities for tasimelteon for the treatment of Non-24-Hour Disorder following the receipt of regulatory approval, if any, research and development activities and other general corporate purposes.

Lazard Capital Markets LLC and Piper Jaffray & Co. are acting as the joint book-running managers of the offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on February 11, 2011. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov. When available, copies of the preliminary prospectus supplement relating to these securities may also be obtained from the offices of Lazard Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York, NY, 10020 or via telephone at (800) 542-0970 or the offices of Piper Jaffray & Co., by mail at 800 Nicollet Mall, J12S03, Minneapolis, MN'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
2. Vanda Pharmaceuticals Reports Second Quarter 2013 Results
3. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
4. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
5. Vanda Pharmaceuticals, Inc. Sued by Investor
6. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
7. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
8. Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
9. Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
10. Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
11. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... of the "Telemedicine and Mobile Healthcare Solutions, ... - 2020" report to their offering. ... are all terms that pertain to the use ... provide remote clinical/non-clinical healthcare services. They form the ...
(Date:3/3/2015)... 2015  Cyberonics, Inc. (NASDAQ: CYBX ), ... and management of epilepsy, today announced it will participate ... 11, 2015, in Miami . ... Executive Officer, will speak at 1:05 PM Eastern Time.  ... format, and no formal materials will be presented.  A ...
(Date:3/3/2015)... Today, the Partnership for Prescription Assistance ... research companies, unveiled a redesigned website ... and caregivers with faster, easier access to information ... assistance programs. Since its launch ... engage, educate and empower patients and caregivers to ...
Breaking Medicine Technology:Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 3Partnership for Prescription Assistance Relaunches Website with New Features for Patients and Caregivers 2
... TAXUS(R) Element(TM) Stent now available in select markets ... (NYSE: BSX ) today announced the ... Coronary Stent System in select markets worldwide. ... chromium alloy engineered specifically for coronary stent applications ...
... Pa., May 18 MEDRAD Interventional(TM)/Possis(R) today announced ... the Paccocath(R) Technology closer to market as an ... the United States and Europe who suffer from ... selection of physician investigators for U.S. clinical trials ...
Cached Medicine Technology:Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 2Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 3Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 4Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 5Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 2Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 3Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 4Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 5
(Date:3/3/2015)... As payers pledge to move the bulk ... next few years, they are testing various initiatives to ... care spending they control — involved. The March issue ... tracks some of the strategies proposed by industry ... organization (ACO)-type model. , One way to get specialists ...
(Date:3/3/2015)... OH (PRWEB) March 03, 2015 On ... amended complaint in the United States District Court for ... and Financial Freedom, as well as insurance companies Balboa, ... 24, 2015 in Case No. 3:14-cv-152.) , The Plaintiff, ... with insurance companies to force her to buy too ...
(Date:3/3/2015)... March 03, 2015 Risperdal lawsuits ... market the atypical antipsychotic medication continue to move ... court documents, the South Carolina Supreme Court upheld ... & Johnson’s Janssen Pharmaceuticals unit had deceptively marketed ... while the Court’s February 25th decision characterized the ...
(Date:3/3/2015)... 2015 Loma Linda University Health announced ... well being, it will be offering new, healthier choices ... , Over the past year, a cross-section of Loma ... dietary criteria, listening to vendors, sampling their products, and ... , Most recently, a food fair was held ...
(Date:3/3/2015)... Today, Steve Weatherford, current New York Giants ... announced the donation of their brains to science during ... Month. In an effort to raise awareness for the ... health, Rice and Weatherford spoke of their experiences on ... brain health a priority to avoid the consequences of ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Examines Ways to Engage Specialists in Value-Based Payment Contracts 2Health News:AIS Newsletter Examines Ways to Engage Specialists in Value-Based Payment Contracts 3Health News:Borrower Accuses Mortgage Lenders of Racketeering in Forcing Insurance on Homeowners 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 3Health News:Loma Linda University Health Rejuvenates Its Vending Machines with Healthier Selections 2Health News:Steve Weatherford and Sidney Rice Reveal Donation for Brain Injury Awareness Month 2
... Leaders for ... World Malaria Day, World ... Bill, WASHINGTON, April 25 A volunteer nurse from,Zambia and ... to emphasize the importance of joint efforts in the,fight against malaria ...
... 24 Amneal Pharmaceuticals, LLC is,pleased to announce ... wholly-owned subsidiary, Amneal Pharmaceuticals of New York, LLC,to ... The,acquisition includes Interpharm,s facilities on Long Island, New ... technology and,processes., Amneal will use its strong ...
... Peddling Video That Does Not Show Attack ... Nurses Will Never Forget SEIU,s Violence, OAKLAND, ... brutal attack on a labor conference in Michigan April 12, ... that,does not show the violence ... as proof that the ...
... say , , THURSDAY, April 24 (HealthDay News) -- Women who ... connects the thighbone to the shinbone. Beyond the immediate pain ... that this type of injury may lead to another vexing ... Rochester, Minn., found that young women who had surgery to ...
... survival when compared to expensive lab tests , , THURSDAY, ... a second-line series of drugs for HIV/AIDS patients who ... the basis of sophisticated and expensive lab tests. , ... slightly affected if these decisions are based instead on ...
... SC, April 24 /PRNewswire/ - Ron Nabors, Chief Executive,Officer ... up with,religious, business and sports leaders in a new ... millions of deaths from,malaria, ahead of the first-ever inaugural ... year, malaria kills more than 1.5 million people in ...
Cached Medicine News:Health News:Government and Corporate Support Together Help Africans Battling Malaria, AIDS 2Health News:Government and Corporate Support Together Help Africans Battling Malaria, AIDS 3Health News:Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm Holdings 2Health News:Nurses Blast SEIU for Deceit in Hiding Violence at Michigan Conference 2Health News:Nurses Blast SEIU for Deceit in Hiding Violence at Michigan Conference 3Health News:Women Risk Bone Loss After Knee Surgery 2Health News:Women Risk Bone Loss After Knee Surgery 3Health News:Clinical Symptoms Enough to Switch Drug Regimens for HIV Patients 2Health News:Clinical Symptoms Enough to Switch Drug Regimens for HIV Patients 3Health News:Executive Director of cbm US congratulates UN on Malaria Campaign 2
... recommended for evaluating vitreoretinal relationships ... in the management of dislocated ... lens for small pupil fundus ... It provides a slightly wider ...
... new MagPlus Iridectomy Lens enhances iridectomy ... viewing area (than conventional iridectomy lens ... The bulb on this lens has ... lens) to 11.7mm. The MagPlus comes ...
... advanced fundus laser lens design with Volk ... magnification viewing and treatment of the optic ... aspheric optics provide improved performance over existing ... comes standard with LaserWindow® for optimal laser ...
... with 10mm diameter contact surface is ideal ... prematurety (ROP) and other infant conditions. It ... in the diagnosis and treatment of the ... with narrow palpebral fissures. Developed with Hideyuki ...
Medicine Products: